ロード中...
Nivolumab and immune‐mediated colitis
Nivolumab is associated with a number of immune‐regulated adverse events, including immune‐mediated colitis and may present following the discontinuation of treatment. Current guidance suggests lower doses of methylprednisolone; however, we described faster resolution of the patient's symptoms...
保存先:
| 出版年: | Clin Case Rep |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6452469/ https://ncbi.nlm.nih.gov/pubmed/30997054 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.2027 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|